Objective To investigate the feasibility of using low-dose prostate CT perfusion (pCTP)on a third-generation dual-source CT. Methods Nine patients with elevated prostate-specific antigen underwent pCTP before having prostate biopsy. We measured the blood flow (BF),blood volume (BV),mean transit time (MTT),permeability surface (PS),and time to peak(TTP)of both lesions and normal prostate tissue. The effective dose (ED)was calculated. Results Of the 9 cases,6 were prostate cancers and 3 were prostate hyperplasia with chronic inflammation. The average ED of the 9 pCTPs was (3.5±0.3)mSv. The BF (t=4.64,P<0.001),BV (t=3.27,P<0.001),and PS (t=3.58,P=0.004)of prostate cancer were significantly higher than those of normal prostate tissue and TTP (t=-1.26,P<0.001)of prostate cancer was significantly lower than that of normal prostate tissue. BF (t=3.96,P=0.001)and PS (t=2.91,P=0.021)of prostate hyperplasia with chronic inflammation were also significantly higher and TTP (t=-1.19,P<0.001)was significantly lower than those of normal prostate tissue. TTP of prostate cancer was significantly lower than that of prostate hyperplasia with chronic inflammation (t=-2.56,P=0.049). Conclusion sLow-dose pCTP is feasible on third-generation dual-source CT. The BF,PS,and TTP differ among prostate cancer,prostate hyperplasia with chronic inflammation,and normal prostate tissue.